Progesterone for Neurodevelopment in Fetuses With Congenital Heart Defects
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.12291 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2024. Verfasst von J William Gaynor und 28 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiothoracic Surgery, Department of Surgery, Children's Hospital of Philadelphia, and the Perelman School of Medicine, University of Pe…. Hauptthemen laut MEDLINE: Progesterone, Heart Defects, Congenital. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.
Abstract (Originalsprache)
Importance Neurodevelopmental outcomes for children with congenital heart defects (CHD) have improved minimally over the past 20 years.
Objectives
To assess the feasibility and tolerability of maternal progesterone therapy as well as the magnitude of the effect on neurodevelopment for fetuses with CHD. Design, Setting, and Participants This double-blinded individually randomized parallel-group clinical trial of vaginal natural progesterone therapy vs placebo in participants carrying fetuses with CHD was conducted between July 2014 and November 2021 at a quaternary care children’s hospital. Participants included maternal-fetal dyads where the fetus had CHD identified before 28 weeks’ gestational age and was likely to need surgery with cardiopulmonary bypass in the neonatal period. Exclusion criteria included a major genetic or extracardiac anomaly other than 22q11 deletion syndrome and known contraindication to progesterone. Statistical analysis was performed June 2022 to April 2024.
Intervention
Participants were 1:1 block-randomized to vaginal progesterone or placebo by diagnosis: hypoplastic left heart syndrome (HLHS), transposition of the great arteries (TGA), and other CHD diagnoses. Treatment was administered twice daily between 28 and up to 39 weeks’ gestational age. Main Outcomes and Measures The primary outcome was the motor score of the Bayley Scales of Infant and Toddler Development-III; secondary outcomes included language and cognitive scales. Exploratory prespecified subgroups included cardiac diagnosis, fetal sex, genetic profile, and maternal fetal environment.
Results
The 102 enrolled fetuses primarily had HLHS (n = 52 [50.9%]) and TGA (n = 38 [37.3%]), were more frequently male (n = 67 [65.7%]), and without genetic anomalies (n = 61 [59.8%]). The mean motor score differed by 2.5 units (90% CI, −1.9 to 6.9 units; P = .34) for progesterone compared with placebo, a value not statistically different from 0. Exploratory subgroup analyses suggested treatment heterogeneity for the motor score for cardiac diagnosis ( P for interaction = .03) and fetal sex ( P for interaction = .04), but not genetic profile ( P for interaction = .16) or maternal-fetal environment ( P for interaction = .70). Conclusions and Relevance In this randomized clinical trial of maternal progesterone therapy, the overall effect was not statistically different from 0. Subgroup analyses suggest heterogeneity of the response to progesterone among CHD diagnosis and fetal sex. Trial Registration ClinicalTrials.gov Identifier: NCT02133573
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiothoracic Surgery, Department of Surgery, Children's Hospital of Philadelphia, and the Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Center for Fetal Diagnosis and Treatment, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Department of Psychology, Children's Hospital of Philadelphia, and the Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Department of Pediatrics, Children's Hospital of Philadelphia, and the Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Division of Anatomic Pathology, Children's Hospital of Philadelphia, and the Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Department of Biostatistics, Epidemiology, and Informatics, the Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Förderung
- NICHD NIH HHS
Zitieren
APA
Gaynor, J. W., Moldenhauer, J. S., Zullo, E. E., Burnham, N. B., Gerdes, M., Bernbaum, J. C., D'Agostino, J. A., Linn, R. L., Klepczynski, B., Randazzo, I., Gionet, G., Choi, G. H., Karaj, A., Russell, W. W., Zackai, E. H., Johnson, M. P., Gebb, J. S., Soni, S., DeBari, S. E., …, & Putt, M. E. (2024). Progesterone for Neurodevelopment in Fetuses With Congenital Heart Defects. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.12291
Vancouver
Gaynor JW, Moldenhauer JS, Zullo EE, Burnham NB, Gerdes M, Bernbaum JC, et al. Progesterone for Neurodevelopment in Fetuses With Congenital Heart Defects. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.12291
BibTeX
@article{Gaynor2024,
author = {Gaynor, J William and Moldenhauer, Julie S and Zullo, Erin E and Burnham, Nancy B and Gerdes, Marsha and Bernbaum, Judy C and D'Agostino, Jo Ann and Linn, Rebecca L and Klepczynski, Brenna and Randazzo, Isabel and Gionet, Gabrielle and Choi, Grace H and Karaj, Antoneta and Russell, William W and Zackai, Elaine H and Johnson, Mark P and Gebb, Juliana S and Soni, Shelly and DeBari, Suzanne E and Szwast, Anita L and Ahrens-Nicklas, Rebecca C and Drivas, Theodore G and Jacobwitz, Marin and Licht, Daniel J and Vossough, Arastoo and Nicolson, Susan C and Spray, Thomas L and Rychik, Jack and Putt, Mary E},
title = {Progesterone for Neurodevelopment in Fetuses With Congenital Heart Defects},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.12291}
}
EUVIMED